Compare Ascendis Pharma A/S (ASND) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Ulta Beauty Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Ulta Beauty Inc trades at $469.2 (market cap $20.17B). The key difference: Ascendis Pharma A/S and Ulta Beauty Inc are close in size by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals.
| ASND | ULTA | |
|---|---|---|
Market Cap | $17.74B | $20.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $706.82 |
52-Week Low | $163.32 | $450.75 |
Enterprise Value | $18.11B | $22.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ULTA Beauty trades at $469.20, up 1.95% on the day, with a bearish technical signal but strong fundamentals including a 9.36% net income margin and 47.45% ROE. Recent Q1 2026 earnings beat expectations at $7.74 EPS versus $6.89. The stock is near its pivot point of $457, with resistance at $470. Positive news highlights international expansion and a robust loyalty program driving 95% of sales.
The outlook is mixed: analyst consensus is bullish with a $623.73 price target, but technicals and recent net cash flow negativity pose risks. Investment opportunity lies in market share gains and AI-driven personalization, while headwinds include competitive pressures and margin compression from 11.42% in 2022 to 9.35% projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
